Finnhub•2026-04-21
Nektar Therapeutics announces pricing of upsized $325 million public offeringNKTR — Nektar Therapeutics
NASDAQ · Pharmaceuticals · Pharmaceuticals
$98.16+92.02%Market cap2.07B
- Latest Close
- $98.16
- 30-Day Move
- +92.0%
- Market Cap
- $2.1B
- Shares Outstanding
- 28,690,000
- P/B Ratio
- 9.57
- ROE
- -182.7%
Analyst consensus: Buy · 16 analysts
NASDAQ:NKTRPharmaceuticals / PharmaceuticalsDelayed public snapshot
Nektar Therapeutics
A read-only Alphactor snapshot forNektar Therapeutics. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$98.16
30-Day Move
+92.0%
Market Cap
$2.1B
Shares Outstanding
28,690,000
P/B Ratio
9.57
ROE
-182.7%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$98.16
+92.0%last 90 delayed daily bars
Market cap$2.1B
90D High
$109.00
90D Low
$33.40
Avg Volume
1,096,813
What stands out
Gross margin is running at 100.0%, which gives a quick read on operating quality before you open the full model.
Net margin is -285.6%, useful for comparing NKTR against peers in Pharmaceuticals.
NKTR is up 92.0% over the last 30 trading days shown on this page.
Latest operating income is $-131M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$7.16
Rule of 40
-421.7%
Fundamentals snapshot
Latest Close
$98.16
30-Day Move
+92.0%
Market Cap
$2.1B
Shares Outstanding
28,690,000
P/B Ratio
9.57
ROE
-182.7%
ROA
-58.5%
Gross Margin
100.0%
Operating Margin
-253.7%
Net Margin
-285.6%
Debt / Equity
0.7
Current Ratio
4.97
Latest Revenue
$55M
Financial statement snapshot
Revenue
$55M
Gross Profit
$55M
Operating Income
$-131M
Net Income
$-164M
Gross Margin
10000.0%
Net Margin
-28559.0%
Current Ratio
4.97
Debt / Equity
0.70
Valuation snapshot
Fair Value
$7.16
Upside / Downside
-92.7%
Signal
Overvalued
Implied Growth
--
EV/Rev
$7.16
Growth Assumption
-10.0%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
Current Price
$98.16
Composite Fair Value
$7.16
EV/Rev
$7.16
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Quality snapshot
Altman Z
-12.70
Distress
Piotroski
3
Weak (0-3)
Cash Conversion
1.27x
Rule of 40
-421.7%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $92M | $-240M | $-368M | $-310M |
| 2023-12-31 | $90M | $-135M | $-276M | $-193M |
| 2024-12-31 | $98M | $-130M | $-119M | $-177M |
| 2025-12-31 | $55M | $-131M | $-164M | $-209M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Benzinga•2026-04-21
Citigroup Maintains Buy on Nektar Therapeutics, Raises Price Target to $151Finnhub•2026-04-21
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming DeadlineBenzinga•2026-04-21
Wedbush Maintains Neutral on Nektar Therapeutics, Raises Price Target to $95SeekingAlpha•2026-04-20
Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage DevelopmentAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$1M
Buys
0
Sells
29
Buy Value
$0
Sell Value
$1M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-18 | Zalevsky Jonathan | Sell | 180 | $73.00 |
| 2026-02-18 | ROBIN HOWARD W | Sell | 423 | $73.00 |
| 2026-01-20 | Zalevsky Jonathan | Sell | 3,867 | $35.67 |
| 2025-12-22 | Zalevsky Jonathan | A | 25,000 | $0.00 |
| 2025-12-22 | Zalevsky Jonathan | A | 6,250 | $0.00 |
| 2025-12-22 | ROBIN HOWARD W | A | 86,667 | $0.00 |
| 2025-12-22 | ROBIN HOWARD W | A | 21,667 | $0.00 |
| 2025-11-25 | Wilson Mark Andrew | Sell | 630 | $54.28 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1,155,001 | 0.04% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 594,509 | 0.02% | 2025-12-31 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 308,614 | 0.01% | 2026-02-28 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 279,460 | 0.01% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 220,482 | 0.01% | 2025-12-31 |
| AIM Growth Series -Invesco Main Street Small Cap Fd. | 179,410 | 0.01% | 2025-12-31 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 178,719 | 0.01% | 2026-01-31 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 140,820 | 0.00% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Charles Schwab
Filed 2025-08-12
--
--
Vanguard Group
Filed 2025-08-11
--
--
Northern Trust
Filed 2025-08-13
--
--
Qube Research & Technologies
Filed 2025-05-15
--
--
Bank of New York Mellon
Filed 2026-02-10
--
--
Invesco
Filed 2025-08-13
--
--
Geode Capital Management
Filed 2025-08-08
--
--
Two Sigma Advisers
Filed 2025-08-14
--
--
Analyst consensus?
Rating(?)
4.31
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
16
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.